|
1. Biologie
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.12 Biopsies liquides
|
|
|
Prostate cancer: Blood test could help target treatment [BBC News]
|
|
|
|
|
|
For
the study, published in the journal Annals of Oncology, scientists took
blood samples from patients taking part in three different clinical
trials. Dr Iain Frame, director of research at Prostate Cancer UK, said
the test could be a significant step towards moving away from a
"one-size-fits-all" approach to treatment.
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.2 Pharma
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
European Commission warns UK over drug authorisation validity due to Brexit [Pharmafile]
|
|
|
|
|
|
In
a statement, the organisation reiterated that, under EU law, it is
required for any authorisation holders to be established in one of the
European Union member states or an EEA country. Given the Britain’s exit
from the Union and its revocation of its status as a member state, drug
companies that are purely UK-based could see their product approvals
disrupted.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
NICE nod for Amgen’s rare leukaemia drug [PharmaTimes]
|
|
|
|
|
|
The
Institute has published final draft guidance recommending Blincyto
(blinatumomab) as an option for treating adults with
Philadelphia-chromosome-negative (Ph-) relapsed or refractory
B-precursor acute lymphoblastic leukaemia (ALL), on the basis of the
discount agreed in the patient access scheme.
|
|
|
|
|
|
|
|
|
5.6.4 ESMO - Poumon
|
|
|
|
5.6.6 ESMO - Sein
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.11 Patients
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
6.7.3 DMP
|
|
|
|
6.9 Controverses
|
|
|
Utah watchdog launches probe of Patrick Soon-Shiong’s controversial donation [STAT]
|
|
|
|
|
|
In
2014, Soon-Shiong gave $12 million to support medical research at the
University of Utah. The contract was worded in such a way that the
university concluded it had no option but to send $10 million of that
money back to one of Soon Shiong’s companies, NantHealth, to conduct the
genetic analysis that would propel the research.
|
|
|
|
|
|